Underlays

Home > Magnetic Therapy Products Information > Magnetic Therapy Products News

Magnetic Therapy Products News

  • Success story: Pain treatments made easy Sunday, August 29, 2010 @ 1:58AMBrad Welch never thought he'd see a chiropractor.
  • Fidelity Biosciences Joins $20M Series C for ViewRay Wednesday, August 25, 2010 @ 1:36PMAisling Capital ViewRayTM, Inc., a privately held medical device company, has secured $20 million in...
  • ViewRay Secures Series C Financing Wednesday, August 25, 2010 @ 10:34AMViewRayâ¢, Inc., a privately held medical device company, has secured $20 million in Series C financing led by new investor Siemens Venture Capital GmbH and joined by existing investors Aisling Capital, Fidelity Biosciences, Kearny Venture Partners and OrbiMed Advisors.
  • Diamond Dust Polishes and Shines to Create Luminous Results in Luxurious Signature Treatments at New Coral Beach Gem Spa Monday, August 23, 2010 @ 8:00AMDiamonds are widely known for being a girl’s best friend, and at the new world-class Gem Spa at the Fiesta Americana Grand Coral Beach Cancún Resort & Spa, they prove to be a best friend and more by creating luminous, healing results. The recently-opened 40,000 square-foot spa features a signature treatment menu utilizing diamond dust through exfoliation and magnetism, all designed to create ...
  • Calendar Thursday, August 12, 2010 @ 4:24AMSubmissions for the Community Calendar are required 10 days preceding the date of publication. Send to: Pioneer Press, 3701 W. Lake Ave., Glenview IL 60026. Information may be faxed to (847) 486-7495 or e-mailed to mbottari@pioneerlocal.com.
  • Long-Term Experience With The DuraHeart™ Left-Ventricular Assist System Continues To Grow As Another Patient Surpasses ... Wednesday, August 11, 2010 @ 6:00AMTerumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, today announced that another patient implanted with the DuraHeart™ Left Ventricular Assist System (LVAS) has surpassed four years after receiving the mechanical circulatory support device. Helga Gieseke, 66, who lives in the south of Saxony-Anhalt, Germany is now one of the longest-living heart failure recipients of this device ...
  • SurModics, EGEN continue collaboration on long-term controlled release of siRNA complexes Wednesday, July 28, 2010 @ 3:50AMSurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry and EGEN, Inc., a privately held biopharmaceutical company focused on developing nucleic acid (DNA and RNAi) therapeutics for the treatment of human diseases, are pleased to announce they have executed a continuation of their feasibility collaboration focused on long-term ...
  • HealthyNewAge.com Launches Natural Healing and Holistic Health News Coverage Tuesday, July 27, 2010 @ 2:01AMHeartCore Corporation announced today that the company is now covering holistic health news. Since 2001, their HealthyNewAge.com web site has published articles on a wide array of alternative healing topics, but this is their first foray into aggregating the news.
  • Neurological Foundation Announces July Grants Monday, July 12, 2010 @ 6:13PMThe Neurological Foundation of New Zealand has today announced research grants, travel grants and scholarships totalling nearly $750,000 for its July 2010 funding round. The Neurological Foundation is the primary non-government sponsor of neurological ...
  • GRI Pumps to Exhibit Pumps for the Original Equipment Manufacturer (OEM) at Intersolar North America Monday, July 12, 2010 @ 12:00PMGorman-Rupp Industries will be exhibiting at Intersolar North America 2010 in San Francisco's Moscone Center West Hall from July 13-15, booth number 7851.
  • Enrollment Underway In CLARITY-AF Study To Compare Efficacy, Safety And Efficiency Of Two Catheter Ablation Technologies Friday, July 9, 2010 @ 7:28AMBiosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study ("CLARITY-AF"), comparing the efficacy, safety and efficiency of CARTO(R) 3 System guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) catheter versus fluoroscopy guided radiofrequency ablation using the ...
  • Reportlinker Adds Nanotechnology and Textiles: Market and Applications to 2015 Tuesday, July 6, 2010 @ 7:15AMReportlinker.com announces that a new market research report is available in its catalogue:
  • Press Release Tuesday, June 29, 2010 @ 6:18AMAMAG Pharmaceuticals Inc. Posted on:29 Jun 10 AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Takeda Pharmaceutical Company Limited (TSE: 4502) today provided a regulatory and clinical update for Feraheme® (ferumoxytol) Injection for intravenous (IV) use.
  • AMAG Pharmaceuticals and Takeda Announce Acceptance of Submission of Feraheme® Marketing Authorization Application to ... Tuesday, June 29, 2010 @ 5:30AMLEXINGTON, Mass. & OSAKA, Japan----AMAG Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today provided a regulatory and clinical update for Feraheme® Injection for intravenous use.
  • Meniscal, cruciate ligament lesions increase risk of knee osteoarthritis Tuesday, June 29, 2010 @ 3:23AMArthroscopic surgical repair of torn anterior cruciate ligaments (ACL) or meniscal cartilage injuries in the knee does not decrease the chances of developing osteoarthritis, according to a new study published in the online edition and August print issue of the journal Radiology.
  • Medical Simulation announces new agreement with New York's North Shore-LIJ Health System Friday, June 18, 2010 @ 1:00AMMedical Simulation Corporation (MSC) proudly announces a new agreement with the North Shore-LIJ Health System, New York's largest health system and recipient of the 2010 National Quality Healthcare Award from the National Quality Forum. The agreement includes the sale of MSC's endovascular simulation system, Simantha®, and licensing of MSC's curriculum and training services to advance North ...
  • Research may lead to better treatments for depression and substance abuse Friday, June 11, 2010 @ 4:42AMIn what has been hailed as a breakthrough, scientists from Columbia University Medical Center and Weill Cornell Medical College have outlined the molecular mechanism of membrane transport. The research shows how a protein transforms its shape to transport substances across the cell membrane in order to regulate transmission of the brain's messages across the synaptic gap from one neuron to ...
  • Do gut bacteria contribute to autism? Tuesday, June 8, 2010 @ 6:23AMGut bacteria may be contributing to autism, suggests a new British study.
  • Do gut bacteria contribute to autism? Tuesday, June 8, 2010 @ 5:02AMLondon, June 8 : Gut bacteria may be contributing to autism, suggests a new British study.
  • Urine test might predict autism Monday, June 7, 2010 @ 8:14AMChildren with autism appear to have a distinctive chemical signature in their urine
  • Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients Monday, June 7, 2010 @ 12:58AM-
  • Freescale Streamlines Health Screenings with Portable Medical Kiosk Friday, June 4, 2010 @ 6:18AMAs the population continues to age and medical monitoring becomes more integrated into everyday living, healthcare professionals are constantly striving to find new ways to monitor patients with improved accuracy, speed and end-user convenience. Taking an active part in this initiative, Freescale Semiconductor , partnering with Pounce Consulting , developed a portable, easy-to-use telemonitoring ...
  • Freescale Streamlines Health Screenings with Portable Medical Kiosk Friday, June 4, 2010 @ 6:00AMGUADALAJARA, Mexico----As the population continues to age and medical monitoring becomes more integrated into everyday living, healthcare professionals are constantly striving to find new ways to monitor patients with improved accuracy, speed and end-user convenience.
  • 26.05.2010 - DJ DGAP-Adhoc: 4SC: Phase II Hodgkin Lymphoma Study with HDAC Inhibitor Resminostat Advances into the ... Wednesday, May 26, 2010 @ 2:37AMDissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement.
  • Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced Friday, May 21, 2010 @ 5:26AMBioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line ...
  • Over 30 Scientific Presentations at ASCO Exploring ABRAXANE's Expanded Potential in Multiple Difficult-to-Treat Cancers Tuesday, May 18, 2010 @ 7:05AMLOS ANGELES----Abraxis BioScience, Inc. today announced that 32 scientific abstracts will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology , June 4-8 in Chicago, evaluating the use of nanoparticle albumin bound driven chemotherapy, nab-paclitaxel .
  • Federal investment in basic research yields outsized dividends Thursday, May 13, 2010 @ 2:51PM(PhysOrg.com) -- Investment in basic scientific research may be one of the best ways to foster long-term economic growth locally and nationally, according to a report released this week by The Science Coalition.
  • Terumo to simultaneously enroll patients in U.S. and Japan for MISAGO Self-expanding Stent System trial Wednesday, May 12, 2010 @ 8:02AMTerumo Medical Corporation, a U.S.-based subsidiary of Terumo Corporation, today announced it has received an investigational device exemption (IDE) conditional approval from the U.S. Food & Drug Administration (FDA) for its Occlusive/Stenotic Peripheral Artery Revascularization Study (OSPREY) in the U.S., which will evaluate the safety and effectiveness of the MISAGO™ Self-expanding Stent ...
  • Watch Tower: Magnetic water treatment Tuesday, May 11, 2010 @ 9:21AMThe basic premise of magnetic water treatment is that when water passes through a strong magnetic field, the minerals in it are affected. The stronger the magnetic field and the longer the water stay in it, the better the effect- Dr SS Verma Definition of diseases has got sea change with the awareness of people about health sciences and so called growing literacy.
  • Fluctuating blood pressure associated with risk of cerebrovascular disease Monday, May 10, 2010 @ 4:21PMThe risk of cerebrovascular diseases appears to be higher among individuals with fluctuating blood pressure in addition to high blood pressure, according to a report in the May issue of Archives of Neurology.
  • MRI: Just as effective as MR arthrography in the diagnosis of hip labral tears Monday, May 10, 2010 @ 4:21PMConventional magnetic resonance imaging (MRI) may be an effective alternative to minimally invasive MR arthrography for the diagnosis of hip labral tears, a common cause of hip pain, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.
  • Keryx Biopharmaceuticals commences Phase 3 registration program for Zerenex Thursday, May 6, 2010 @ 8:49AMKeryx Biopharmaceuticals, Inc. announced today the initiation of its short-term Phase 3 study of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.
  • C. R. Bard reaches definitive agreement to acquire SenoRx Wednesday, May 5, 2010 @ 11:48PMC. R. Bard, Inc. today announced that it has reached a definitive agreement to acquire SenoRx, Inc. (Nasdaq: SENO), for a purchase price of $11.00 per share in cash, totaling approximately $200 million, net of cash acquired.
  • AdvaCAL named official partner of National Osteoporosis Foundation Wednesday, May 5, 2010 @ 12:19AMAdvaCAL® calcium supplements is proud to announce that it has been named as an official partner of the National Osteoporosis Foundation (NOF), the nations' leading voluntary health organization dedicated to osteoporosis and bone health. This designation is reserved for companies that provide financial support to NOF, with products judged to be consistent with the NOF mission.
  • Drug makers enter crucial phase in search for Alzheimer's disease treatments Tuesday, May 4, 2010 @ 11:52AMReporting from Chicago — After decades of research and multiple failed attempts to find a treatment, the pharmaceutical industry is entering a crucial phase in the search for a drug that can slow, or stop, the progression of Alzheimer's disease .
  • Hope on Alzheimer drug front Sunday, May 2, 2010 @ 8:45PMResearch on 5 Alzheimer's treatments is in critical final-stage trials that companies and doctors hope will lead to FDA-approved disease-modifying therapies After decades of research and multiple failed attempts to find a treatment, the pharmaceutical industry is entering a critical phase in the search for a drug that can slow, or stop, the progression of Alzheimer's disease.
  • Hope on Alzheimer drug front Sunday, May 2, 2010 @ 8:45PMResearch on 5 Alzheimer's treatments is in critical final-stage trials that companies and doctors hope will lead to FDA-approved disease-modifying therapies After decades of research and multiple failed attempts to find a treatment, the pharmaceutical industry is entering a critical phase in the search for a drug that can slow, or stop, the progression of Alzheimer's disease.
  • AFFiRiS AG's AD02 Alzheimer's vaccine candidate in phase II clinical testing Saturday, April 24, 2010 @ 12:47AMAFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing ...
  • Potential new early cancer detection method using engineered gold nanoparticles Friday, April 23, 2010 @ 2:33AMUniversity of Missouri School of Medicine scientists explain a potentially new early cancer detection and treatment method using nanoparticles created at MU in an article published in the Proceedings of the National Academy of Sciences. The article illustrates how engineered gold nanoparticles tied to a cancer-specific receptor could be targeted to tumor cells to treat prostate, breast or lung ...
  • UMass Amherst Chemists Clarify Protein-Receptor Complex's Role In Iron Uptake To Cells Friday, April 23, 2010 @ 12:41AMIn recent years cancer researchers, particularly brain tumor specialists, have pinned some hope for delivering anti-tumor drugs on transferrin, a protein that carries the essential element iron into cells.
  • Columbia Laboratories' net revenues from US progesterone sales for first-quarter up 36% Thursday, April 22, 2010 @ 6:21AMColumbia Laboratories, Inc. today announced preliminary results for the quarter ended March 31, 2010.
  • Biotherapy Thursday, April 22, 2010 @ 1:35AM‘Biotherapy? In La Mesa?” asked my husband as we strolled through town admiring the new shops. “Sounds like something you should check out.”
  • NST Online Wednesday, April 21, 2010 @ 12:43PMSpectacles for children HOW do you tell if your child needs glasses? Generally, their behaviour will give parents clues. Are they sitting very close to the television or reading books too closely? If they have started school, talk to their teachers about how they are behaving in school.
  • Abbott's first-quarter worldwide pharmaceutical sales increases by 12.9% Wednesday, April 21, 2010 @ 7:09AMAbbott today announced financial results for the first quarter ended March 31, 2010.
  • Community Calendar Thursday, April 15, 2010 @ 4:04AMSubmissions for Community Calendar are required 14 days preceding the date of publication. Send to: Niles Managing Editor, Pioneer Press, 3701 W. Lake Ave., Glenview IL 60026. Information may be faxed to (847) 486-7495 or e-mailed to mbottari@pioneerlocal.com.
  • Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced Thursday, April 15, 2010 @ 1:19AMBaxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and ...
  • Terumo Heart, Inc. Submits IDE to FDA for U.S. Destination Therapy Trial for the DuraHeart(TM) Left Ventricular Assist ... Wednesday, April 14, 2010 @ 6:00AMTerumo Heart Inc., a wholly owned subsidiary of Terumo Corporation, today announced the submission of its Destination Therapy Investigational Device Exemption to the FDA for its DuraHeart⢠Left-Ventricular Assist System .  This is a first step in the process of obtaining approval to begin its DuraHeart DT Clinical Trial in the U.S.
  • Press Release Friday, April 9, 2010 @ 3:40AMWaterloo, Belgium, (April 8, 2010) Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO® 3 System-guided radiofrequency ablation using the NAVISTAR® THERMOCOOL® Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter® (PVAC® ...
  • Press Release Friday, April 9, 2010 @ 3:25AMBiosense Webster Inc. Posted on:08 Apr 10 WATERLOO, Belgium, April 8, 2010 /PRNewswire/ -- Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ...
  • Bringing "CLARITY" on Efficacy, Safety and Efficiency of Catheter Ablation of Atrial Fibrillation Thursday, April 8, 2010 @ 5:28PMWATERLOO, Belgium, April 8, 2010 /PRNewswire/ -- Biosense Webster announces that this week it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO(R) 3 System-guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein ...